Select a medication above to begin.
Kadcyla
ado-trastuzumab emtansine
Black Box Warnings .
Hepatotoxicity
serious hepatotoxicity reported, incl. hepatic failure and death; monitor LFTs at baseline, then prior to each cycle; decr. dose or D/C tx if elevated LFTs
Cardiotoxicity
may result in decr. LVEF; monitor LVEF at baseline, then q3mo; D/C tx if clinically significant decr. in LVEF
Embryo-Fetal Toxicity
exposure during pregnancy can result in embryo-fetal death or birth defects; advise pts of risks and need for effective contraception
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: not interchangeable w/ fam-trastuzumab deruxtecan or other trastuzumab-containing products
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
HER2-positive breast CA
- [adjuvant tx]
- Dose: 3.6 mg/kg/dose IV x1 on day 1 of 21-day cycle x14 cycles; Info: for pts w/ residual invasive dz post neoadjuvant taxane- and trastuzumab-based tx
- [metastatic dz]
- Dose: 3.6 mg/kg/dose IV x1 on day 1 of 21-day cycle; Info: for taxane- and trastuzumab-refractory dz
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.